Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells

Journal of Cell Science

Volumn 127, Issue 16, 2014, Pages 3555-3567

  Furcht, Christopher M ^a   Buonato, Janine M ^a   Skuli, Nicolas ^b,c   Mathew, Lijoy K ^b,c   Muñoz Rojas, Andrés R ^a   Simon, M Celeste ^b,c   Lazzara, Matthew J ^a,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Extracellular signal regulated kinase 1 2 (ERK1 2); Gefitinib; HGF receptor (c MET); Hypoxia inducible factors; Signal transducer and activator of transcription 3 (STAT3)

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT3 PROTEIN; STATTIC; UNCLASSIFIED DRUG; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; INDOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DECISION MAKING; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR RESISTANCE; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLIOBLASTOMA; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MICE, NUDE; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; SULFONES;

EID: 84906070874     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.150862     Document Type: Article

References (49)

1. Aceto, N., Sausgruber, N., Brinkhaus, H., Gaidatzis, D., Martiny-Baron, G., Mazzarol, G., Confalonieri, S., Quarto, M., Hu, G., Balwierz, P. J. et al. (2012). Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat. Med. 18, 529-537.
2. Agazie, Y. M. and Hayman, M. J. (2003). Development of an efficient "substratetrapping"mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. J. Biol. Chem. 278, 13952-13958.
3. Amin, A. R., Thakur, V. S., Paul, R. K., Feng, G. S., Qu, C. K., Mukhtar, H. and Agarwal, M. L. (2007). SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc. Natl. Acad. Sci. USA 104, 5419-5424.
4. Argyriou, A. A. and Kalofonos, H. P. (2009). Molecularly targeted therapies for malignant gliomas. Mol. Med. 15, 115-122.
5. Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V. et al. (2011). Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629-639.
6. Cai, T., Nishida, K., Hirano, T. and Khavari, P. A. (2002). Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J. Cell Biol. 159, 103-112.
7. Chan, R. J. and Feng, G. S. (2007). PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109, 862-867.
8. Chan, G., Kalaitzidis, D. and Neel, B. G. (2008). The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27, 179-192.
9. Chung, J., Uchida, E., Grammer, T. C. and Blenis, J. (1997). STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 17, 6508-6516.
10. Dauer, D. J., Ferraro, B., Song, L., Yu, B., Mora, L., Buettner, R., Enkemann, S., Jove, R. and Haura, E. B. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397-3408.
11. de la Iglesia, N., Puram, S. V. and Bonni, A. (2009). STAT3 regulation of glioblastoma pathogenesis. Curr. Mol. Med. 9, 580-590.
12. De Witt Hamer, P. C. (2010). Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-oncol. 12, 304-316.
13. Fan, Q. W., Cheng, C. K., Gustafson, W. C., Charron, E., Zipper, P., Wong, R. A., Chen, J., Lau, J., Knobbe-Thomsen, C., Weller, M. et al. (2013). EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 24, 438-449.
14. Furcht, C. M., Munoz Rojas, A. R., Nihalani, D. and Lazzara, M. J. (2012). Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. Oncogene 32, 2346-2355, e1-e10.
15. Grandal, M. V., Zandi, R., Pedersen, M. W., Willumsen, B. M., van Deurs, B. and Poulsen, H. S. (2007). EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28, 1408-1417.
16. Gu, H. and Neel, B. G. (2003). The "Gab"in signal transduction. Trends Cell Biol. 13, 122-130.
17. Hodge, D. R., Hurt, E. M. and Farrar, W. L. (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502-2512.
18. Huang, H. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X. D., Huang, C. M., Gill, G. N., Wiley, H. S. and Cavenee, W. K. (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935.
19. Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Brewer, Z. E., Cavenee, W. K., Furnari, F. B. and White, F. M. (2007). Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. USA 104, 12867-12872.
20. Janes, K. A., Albeck, J. G., Gaudet, S., Sorger, P. K., Lauffenburger, D. A. and Yaffe, M. B. (2005). A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310, 1646-1653.
21. Krens, S. F., Corredor-Adámez, M., He, S., Snaar-Jagalska, B. E. and Spaink, H. P. (2008). ERK1 and ERK2 MAPK are key regulators of distinct gene sets in zebrafish embryogenesis. BMC Genomics 9, 196.
22. Kumar, N., Wolf-Yadlin, A., White, F. M. and Lauffenburger, D. A. (2007). Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. PLOS Comput. Biol. 3, e4.
23. Lal, B., Goodwin, C. R., Sang, Y., Foss, C. A., Cornet, K., Muzamil, S., Pomper, M. G., Kim, J. and Laterra, J. (2009). EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol. Cancer Ther. 8, 1751-1760.
24. Lazzara, M. J. and Lauffenburger, D. A. (2009). Quantitative modeling perspectives on the ErbB system of cell regulatory processes. Exp. Cell Res. 315, 717-725.
25. Lazzara, M. J., Lane, K., Chan, R., Jasper, P. J., Yaffe, M. B., Sorger, P. K., Jacks, T., Neel, B. G. and Lauffenburger, D. A. (2010). Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res. 70, 3843-3850.
26. Lo, H. W., Cao, X., Zhu, H. and Ali-Osman, F. (2008). Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in highgrade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin. Cancer Res. 14, 6042-6054.
27. Lu, Z. and Xu, S. (2006). ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58, 621-631.
28. Lund, K. A., Opresko, L. K., Starbuck, C., Walsh, B. J. and Wiley, H. S. (1990). Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J. Biol. Chem. 265, 15713-15723.
29. Moscatello, D. K., Holgado-Madruga, M., Godwin, A. K., Ramirez, G., Gunn, G., Zoltick, P. W., Biegel, J. A., Hayes, R. L. and Wong, A. J. (1995). Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55, 5536-5539.
30. Moscatello, D. K., Montgomery, R. B., Sundareshan, P., McDanel, H., Wong, M. Y. and Wong, A. J. (1996). Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13, 85-96.
31. Neel, B. G., Gu, H. and Pao, L. (2003). The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284-293.
32. Roberts, P. J. and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310.
33. Sathornsumetee, S., Reardon, D. A., Desjardins, A., Quinn, J. A., Vredenburgh, J. J. and Rich, J. N. (2007). Molecularly targeted therapy for malignant glioma. Cancer 110, 13-24.
34. Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C. and Schaper, F. (2000). SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275, 12848-12856.
35. Shao, H., Cheng, H. Y., Cook, R. G. and Tweardy, D. J. (2003). Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 63, 3923-3930.
36. Sturla, L. M., Zinn, P. O., Ng, K., Nitta, M., Kozono, D., Chen, C. C. and Kasper, E. M. (2011). Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br. J. Cancer 105, 1235-1243.
37. Tykocinski, E. S., Grant, R. A., Kapoor, G. S., Krejza, J., Bohman, L. E., Gocke, T. A., Chawla, S., Halpern, C. H., Lopinto, J., Melhem, E. R. et al. (2012). Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro-oncol. 14, 613-623.
38. Ventura, A., Meissner, A., Dillon, C. P., McManus, M., Sharp, P. A., Van Parijs, L., Jaenisch, R. and Jacks, T. (2004). Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. USA 101, 10380-10385.
39. Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N. et al. (2012). Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2, 458-471.
40. Wiley, H. S. and Cunningham, D. D. (1982). The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis. J. Biol. Chem. 257, 4222-4229.
41. Wolf-Yadlin, A., Kumar, N., Zhang, Y., Hautaniemi, S., Zaman, M., Kim, H. D., Grantcharova, V., Lauffenburger, D. A. and White, F. M. (2006). Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst. Biol. 2, 54.
42. Wu, C. J., O'Rourke, D. M., Feng, G. S., Johnson, G. R., Wang, Q. and Greene, M. I. (2001). The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 20, 6018-6025.
43. Yu, H. and Jove, R. (2004). The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4, 97-105.
44. Zhan, Y. and O'Rourke, D. M. (2004). SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival. Cancer Res. 64, 8292-8298.
45. Zhan, Y., Counelis, G. J. and O'Rourke, D. M. (2009). The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp. Cell Res. 315, 2343-2357.
46. Zhang, W. and Liu, H. T. (2002). MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12, 9-18.
47. Zhang, S. Q., Tsiaras,W. G., Araki, T.,Wen, G., Minichiello, L., Klein, R. and Neel, B. G. (2002). Receptor-specific regulation of phosphatidylinositol 39-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell. Biol. 22, 4062-4072.
48. Zhang, X., Zhang, W., Cao, W. D., Cheng, G. and Zhang, Y. Q. (2012). Glioblastoma multiforme: Molecular characterization and current treatment strategy. Exp. Ther Med. 3, 9-14.
49. Zhou, X. and Agazie, Y. M. (2009). Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J. Biol. Chem. 284, 12226-12234